The use of self-adjuvanting nanofiber vaccines to elicit high-affinity B cell responses to peptide antigens without inflammation

Biomaterials

Volumn 34, Issue 34, 2013, Pages 8776-8785

  Chen, Jianjun ^a   Pompano, Rebecca R ^a   Santiago, Felix W ^b   Maillat, Lea ^a   Sciammas, Roger ^a   Sun, Tao ^a   Han, Huifang ^a   Topham, David J ^b   Chong, Anita S ^a   Collier, Joel H ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Alum adjuvant; Nanoparticle vaccines; Non reactogenic; OVA(323 339) peptide; Self assembly

Indexed keywords

ALUM ADJUVANT; ANTIBODY RESPONSE; COMPLETE FREUND'S ADJUVANTS; GERMINAL CENTERS; INFLAMMATORY CELLS; INHIBITION ASSAYS; NANO PARTICULATES; NON-REACTOGENIC;

ANTIGEN-ANTIBODY REACTIONS; CELLS; CYTOLOGY; EPITOPES; NANOFIBERS; PATHOLOGY; PEPTIDES; SELF ASSEMBLY;

VACCINES;

ALUM ADJUVANTED VACCINE; ALUMINUM POTASSIUM SULFATE; ANTIGEN; B7 ANTIGEN; CD86 ANTIGEN; CYTOKINE; DIFFERENTIATION ANTIGEN; EPITOPE; FREUND ADJUVANT; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; MARKER; NANOFIBER; PEPTIDE; SELF ADJUVANTING NANOFIBER VACCINE; UNCLASSIFIED DRUG; VACCINE;

ANIMAL CELL; ANTIBODY RESPONSE; ARTICLE; B LYMPHOCYTE; BETA SHEET; DENDRITIC CELL; GERMINAL CENTER; HELPER CELL; IMMUNIZATION; IMMUNOGENICITY; IMMUNOTHERAPY; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; INFLAMMATORY CELL; INJECTION SITE; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SWELLING; T LYMPHOCYTE;

MUS;

ALUM ADJUVANT; NANOPARTICLE VACCINES; NON-REACTOGENIC; OVA(323-339) PEPTIDE; SELF ASSEMBLY;

ADJUVANTS, IMMUNOLOGIC; ALUM COMPOUNDS; ANIMALS; ANTIBODY FORMATION; ANTIGENS, CD80; ANTIGENS, CD86; B-LYMPHOCYTES; BIOCOMPATIBLE MATERIALS; CYTOKINES; DENDRITIC CELLS; EPITOPES; INFLAMMATION; MICE; MICE, INBRED C57BL; NANOFIBERS; PEPTIDES; T-LYMPHOCYTES, HELPER-INDUCER; TOLL-LIKE RECEPTOR 4; VACCINES, SUBUNIT;

EID: 84882924297     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.07.063     Document Type: Article

References (57)

1. Aguilar J.C., Rodriguez E.G. Vaccine adjuvants revisited. Vaccine 2007, 25:3752-3762.
2. Reed S.G., Bertholet S., Coler R.N., Friede M. New horizons in adjuvants for vaccine development. Trends Immunol 2009, 30:23-32.
3. Dekker C.L., Gordon L., Klein J. Dose optimization strategies for vaccines: the role of adjuvants and new technologies 2008, Vaccine Development and Supply Subcommittee of the National Vaccine Advisory Committee.
4. Gupta R.K. Aluminum compounds as vaccine adjuvants. Adv Drug Deliv Rev 1998, 32:155-172.
5. Cain D.W., Sanders S.E., Cunningham M.M., Kelsoe G. Disparate adjuvant properties among three formulations of "alum". Vaccine 2013, 31:653-660.
6. Purcell A.W., McCluskey J., Rossjohn J. More than one reason to rethink the use of peptides in vaccine design. Nat Rev Drug Discov 2007, 6:404-414.
7. Jennings G.T., Bachmann M.F. Coming of age of virus-like particle vaccines. Biol Chem 2008, 389:521-536.
8. Tissot A.C., Renhofa R., Schmitz N., Cielens I., Meijerink E., Ose V., et al. Versatile virus-like particle carrier for epitope based vaccines. PLoS One 2010, 5:e9809.
9. Kaba S.A., Brando C., Guo Q., Mittelholzer C., Raman S., Tropel D., et al. Anonadjuvanted polypeptide nanoparticle vaccine confers long-lasting protection against rodent malaria. JImmunol 2009, 183:7268-7277.
10. Kaba S.A., McCoy M.E., Doll T., Brando C., Guo Q., Dasgupta D., et al. Protective antibody and CD8(+) T-Cell responses to the Plasmodium falciparum circumsporozoite protein induced by a nanoparticle vaccine. PLoS One 2012, 7:e48304.
11. Bershteyn A., Hanson M.C., Crespo M.P., Moon J.J., Li A.V., Suh H., et al. Robust IgG responses to nanograms of antigen using a biomimetic lipid-coated particle vaccine. JControl Release 2012, 157:354-365.
12. Fifis T., Mottram P., Bogdanoska V., Hanley J., Plebanski M. Short peptide sequences containing MHC class I and/or class II epitopes linked to nano-beads induce strong immunity and inhibition of growth of antigen-specific tumour challenge in mice. Vaccine 2004, 23:258-266.
13. Reddy S.T., van der Vlies A.J., Simeoni E., Angeli V., Randolph G.J., O'Neill C.P., et al. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat Biotechnol 2007, 25:1159-1164.
14. Ulery B.D., Kumar D., Ramer-Tait A.E., Metzger D.W., Wannemuehler M.J., Narasimhan B. Design of a protective single-dose intranasal nanoparticle-based vaccine platform for respiratory infectious diseases. PLoS One 2011, 6:e17642.
15. Rudra J.S., Mishra S., Chong A.S., Mitchell R.A., Nardin E.H., Nussenzweig V., et al. Self-assembled peptide nanofibers raising durable antibody responses against a malaria epitope. Biomaterials 2012, 33:6476-6484.
16. Rudra J.S., Sun T., Bird K.C., Daniels M.D., Gasiorowski J.Z., Chong A.S., et al. Modulating adaptive immune responses to peptide self-assemblies. ACS Nano 2012, 6:1557-1564.
17. Rudra J.S., Tian Y.F., Jung J.P., Collier J.H. Aself-assembling peptide acting as an immune adjuvant. Proc Natl Acad Sci U S A 2010, 107:622-627.
18. Moon J.J., Huang B., Irvine D.J. Engineering nano- and microparticles to tune immunity. Adv Mater 2012, 24:3724-3746.
19. Bachmann M.F., Jennings G.T. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol 2010, 10:787-796.
20. Reddy S.T., Swartz M.A., Hubbell J.A. Targeting dendritic cells with biomaterials: developing the next generation of vaccines. Trends Immunol 2006, 27:573-579.
21. Sharp F.A., Ruane D., Claass B., Creagh E., Harris J., Malyala P., et al. Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome. Proc Natl Acad Sci U S A 2009, 106:870-875.
22. Petersen L.K., Ramer-Tait A.E., Broderick S.R., Kong C.S., Ulery B.D., Rajan K., et al. Activation of innate immune responses in a pathogen-mimicking manner by amphiphilic polyanhydride nanoparticle adjuvants. Biomaterials 2011, 32:6815-6822.
23. Torres M.P., Wilson-Welder J.H., Lopac S.K., Phanse Y., Carrillo-Conde B., Ramer-Tait A.E., et al. Polyanhydride microparticles enhance dendritic cell antigen presentation and activation. Acta Biomater 2011, 7:2857-2864.
24. Ulery B.D., Petersen L.K., Phanse Y., Kong C.S., Broderick S.R., Kumar D., et al. Rational design of pathogen-mimicking amphiphilic materials as nanoadjuvants. Sci Rep 2011, 1:198.
25. Lewis J.S., Zaveri T.D., Crooks C.P., Keselowsky B.G. Microparticle surface modifications targeting dendritic cells for non-activating applications. Biomaterials 2012, 33:7221-7232.
26. Huntimer L., Ramer-Tait A.E., Petersen L.K., Ross K.A., Walz K.A., Wang C., et al. Evaluation of biocompatibility and administration site reactogenicity of polyanhydride-particle-based platform for vaccine delivery. Adv Healthc Mater 2013, 2:369-378.
27. Jung J.P., Nagaraj A.K., Fox E.K., Rudra J.S., Devgun J.M., Collier J.H. Co-assembling peptides as defined matrices for endothelial cells. Biomaterials 2009, 30:2400-2410.
28. Jung J.P., Jones J.L., Cronier S.A., Collier J.H. Modulating the mechanical properties of self-assembled peptide hydrogels via native chemical ligation. Biomaterials 2008, 29:2143-2151.
29. Thomas P.G., Brown S.A., Yue W., So J., Webby R.J., Doherty P.C. An unexpected antibody response to an engineered influenza virus modifies CD8+ T cell responses. Proc Natl Acad Sci U S A 2006, 103:2764-2769.
30. Marichal T., Ohata K., Bedoret D., Mesnil C., Sabatel C., Kobiyama K., et al. DNA released from dying host cells mediates aluminum adjuvant activity. Nat Med 2011, 17:996-1002.
31. Kool M., Soullie T., van Nimwegen M., Willart M.A.M., Muskens F., Jung S., et al. Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. JExp Med 2008, 205:869-882.
32. HogenEsch H. Mechanism of immunopotentiation and safety of aluminum adjuvants. Front Immunol 2013, 3:406.
33. Goto N., Kato H., Maeyama J., Shibano M., Saito T., Yamaguchi J., et al. Local tissue irritating effects and adjuvant activities of calcium phosphate and aluminium hydroxide with different physical properties. Vaccine 1997, 15:1364-1371.
34. Seubert A., Calabro S., Santini L., Galli B., Genovese A., Valentini S., et al. Adjuvanticity of the oil-in-water emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88. Proc Natl Acad Sci U S A 2011, 108:11169-11174.
35. McKee A.S., Munks M.W., MacLeod M.K.L., Fleenor C.J., Van Rooijen N., Kappler J.W., et al. Alum induces innate immune responses through macrophage and mast cell sensors, but these sensors are not required for alum to act as an adjuvant for specific immunity. JImmunol 2009, 183:4403-4414.
36. Calabro S., Tortoli M., Baudner B.C., Pacitto A., Cortese M., O'Hagan D.T., et al. Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes. Vaccine 2011, 29:1812-1823.
37. Crotty S. Follicular helper CD4 T cells (T-fh). Annu Rev Immunol 2011, 29:621-663.
38. Huang Z.H., Shi L., Ma J.W., Sun Z.Y., Cai H., Chen Y.X., et al. Atotally synthetic, self-assembling, adjuvant-free MUC1 glycopeptide vaccine for cancer therapy. JAm Chem Soc 2012, 134:8730-8733.
39. Jackson D.C., Purcell A.W., Fitzmaurice C.J., Zeng W., Hart D.N.J. The central role played by peptides in the immune response and the design of peptide-based vaccines against infectious diseases and cancer. Curr Drug Targets 2002, 3:175-196.
40. Lanzavecchia A., Sallusto F. Toll-like receptors and innate immunity in B-cell activation and antibody responses. Curr Opin Immunol 2007, 19:268-274.
41. Malyala P., Singh M. Endotoxin limits in formulations for preclinical research. JPharm Sci 2008, 97:2041-2044.
42. Ohmit S.E., Petrie J.G., Cross R.T., Johnson E., Monto A.S. Influenza hemagglutination-inhibition antibody titer as a correlate of vaccine-induced protection. JInfect Dis 2011, 204:1879-1885.
43. Banzhoff A., Pellegrini M., Del Giudice G., Fragapane E., Groth N., Podda A. MF59 (R)-adjuvanted vaccines for seasonal and pandemic influenza prophylaxis. Influenza Other Respir Viruses 2008, 2:243-249.
44. Vogel F.R., Caillet C., Kusters I.C., Haensler J. Emulsion-based adjuvants for influenza vaccines. Exp Rev Vaccines 2009, 8:483-492.
45. Baldwin S.L., Shaverdian N., Goto Y., Duthie M.S., Raman V.S., Evers T., et al. Enhanced humoral and Type 1 cellular immune responses with Fluzone (R) adjuvanted with a synthetic TLR4 agonist formulated in an emulsion. Vaccine 2009, 27:5956-5963.
46. Clegg C.H., Roque R., Van Hoeven N., Perrone L., Baldwin S.L., Rininger J.A., et al. Adjuvant solution for pandemic influenza vaccine production. Proc Natl Acad Sci U S A 2012, 109:17585-17590.
47. Coler R.N., Bertholet S., Moutaftsi M., Guderian J.A., Windish H.P., Baldwin S.L., et al. Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant. PLoS One 2011, 6:e16333.
48. Skwarczynski M., Toth I. Peptide-based subunit nanovaccines. Curr Drug Deliv 2011, 8:282-289.
49. Swartz M.A., Hirosue S., Hubbell J.A. Engineering approaches to immunotherapy. Sci Transl Med 2012, 4:148rv9.
50. Malyala P., Chesko J., Ugozzoli M., Goodsell A., Zhou F., Vajdy M., et al. The potency of the adjuvant, CpG oligos, is enhanced by encapsulation in PLG microparticles. JPharm Sci 2008, 97:1155-1164.
51. Moon J.J., Suh H., Li A.V., Ockenhouse C.F., Yadava A., Irvine D.J. Enhancing humoral responses to a malaria antigen with nanoparticle vaccines that expand T-fh cells and promote germinal center induction. Proc Natl Acad Sci U S A 2012, 109:1080-1085.
52. De Geest B.G., Willart M.A., Hammad H., Lambrecht B.N., Pollard C., Bogaert P., et al. Polymeric multilayer capsule-mediated vaccination induces protective immunity against cancer and viral infection. ACS Nano 2012, 6:2136-2149.
53. Collier J.H. Modular self-assembling biomaterials for directing cellular responses. Soft Matter 2008, 4:2310-2315.
54. Jung J.P., Moyano J.V., Collier J.H. Multifactorial optimization of endothelial cell growth using modular synthetic extracellular matrices. Integr Biol 2011, 3:185-196.
55. Thomas S.N., van der Vlies A.J., O'Neil C.P., Reddy S.T., Yu S.S., Giorgio T.D., et al. Engineering complement activation on polypropylene sulfide vaccine nanoparticles. Biomaterials 2011, 32:2194-2203.
56. Black M., Trent A., Kostenko Y., Lee J.S., Olive C., Tirrell M. Self-assembled peptide amphiphile micelles containing a cytotoxic T-Cell epitope promote a protective immune response invivo. Adv Mater 2012, 24:3845-3849.
57. Hirosue S., Kourtis I.C., van der Vlies A.J., Hubbell J.A., Swartz M.A. Antigen delivery to dendritic cells by poly(propylene sulfide) nanoparticles with disulfide conjugated peptides: cross-presentation and T cell activation. Vaccine 2010, 28:7897-7906.